SNDX Syndax Pharmaceuticals Inc.

6.65
+0.29  (+5%)
Previous Close 6.36
Open 6.4
Price To Book 3.26
Market Cap 180,459,680
Shares 27,136,794
Volume 158,869
Short Ratio
Av. Daily Volume 175,642
Stock charts supplied by TradingView

NewsSee all news

  1. Syndax Announces Participation at Four Upcoming Investor Conferences

    WALTHAM, Mass., Aug. 28, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 top-line data March 7, 2019 failed to meet endpoints.
Entinostat plus Tecentriq - ENCORE 603
Ovarian cancer
Phase 2 top-line data March 7, 2019 failed to meet endpoints.
Entinostat plus Tecentriq - ENCORE 602
Triple negative breast cancer (TNBC)
Phase 2 updated data to be presented September 24, 2018 did not meet prespecified ORR endpoint.
Entinostat plus Keytruda - ENCORE 601
Recurrent non-small cell lung cancer (NSCLC), colorectal cancer
Phase 3 PFS date did not meet primary endpoint - October 25, 2018. OS final analysis due 2Q 2020.
E2112
HR+, HER2- breast cancer
Phase 1 initial data due 2H 2020.
SNDX-6352
Chronic graft versus host disease
Phase 1/2 data due in 2020.
SNDX-5613
Relapsed/refractory (R/R) acute leukemias

Latest News

  1. Syndax Announces Participation at Four Upcoming Investor Conferences

    WALTHAM, Mass., Aug. 28, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative